Effect of thalidomide in patients with chronic heart failure

Related Experiment Video

Updated: Sep 28, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Lars Gullestad1, Anne Grete Semb, Even Holt

  • 1Department of Internal Medicine, Baerum Hospital, Aker Hospital, Oslo, Norway. lars.gullestad@broadpark.no

American Heart Journal
|November 8, 2002
PubMed

Insights

Thalidomide treatment reduced tumor necrosis factor-alpha (TNF-alpha) and improved cardiac function in patients with congestive heart failure (CHF). This pilot study suggests thalidomide may be a beneficial immunomodulating agent for CHF.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) is linked to heightened immune activation, potentially driving disease progression.
  • Investigating immunomodulatory therapies is crucial for managing CHF.

Purpose of the Study:

  • To assess the efficacy of thalidomide, an immunomodulating drug, in improving cardiac performance in CHF patients.
  • To evaluate the impact of thalidomide on tumor necrosis factor-alpha (TNF-alpha) levels in CHF.

Main Methods:

  • A 6-week open-label pilot study involving nine CHF patients with left ventricular ejection fraction (LVEF) <40%.
  • Patients received 200 mg of thalidomide daily alongside optimal conventional cardiovascular treatment.
  • Measurements included plasma TNF-alpha levels and LVEF at baseline and study completion.

Main Results:

  • Thalidomide therapy led to a significant decrease in elevated TNF-alpha levels.
  • LVEF significantly improved from 26% to 34% in patients receiving thalidomide.
  • Sedation was a common side effect, necessitating dose reduction in most participants.

Conclusions:

  • Thalidomide demonstrated potential in reducing TNF-alpha and enhancing cardiac performance in CHF patients.
  • Further investigation of thalidomide as an immunomodulating agent for CHF is warranted.
  • The study highlights the role of immune pathways in CHF pathogenesis.
Abstract

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...